The Pneumonia Therapeutics Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global market for pneumonia therapeutics has significantly expanded recently. The market worth rose from $10.35 billion in 2024 and is predicted to reach $11.49 billion in 2025, progressing at a compound annual growth rate (CAGR) of 11.0%.
The Pneumonia Therapeutics Global Market is projected to grow to a size of $17.26 billion by 2029, with a compound annual growth rate (CAGR) of 10.7%.
Download Your Free Sample of the 2025 Pneumonia Therapeutics Market Report and Uncover Key Trends Now!The key drivers in the pneumonia therapeutics market are:
• Increasing prevalence of antibiotic-resistant strains of pneumonia
• Growth of aging populations that are more prone to pneumonia
• Expansion of telemedicine for early detection and treatment of pneumonia
• Rising funding for infectious disease research and awareness campaigns
The pneumonia therapeutics market covered in this report is segmented –
1) By Product: Drugs, Vaccine, Oxygen Therapy
2) By Infection: Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Ventilator-Associated Pneumonia (VAP)
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End Use: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Drugs: Antibiotics, Antiviral Drugs, Antifungal Drugs, Corticosteroids, Other Drugs
2) By Vaccine: Pneumococcal Vaccines, Haemophilus Influenzae Type B (Hib) Vaccines, Influenza Vaccines, Other Vaccines
3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC), Non-Invasive Ventilation (NIV), Mechanical Ventilation, Other Oxygen Therapies
The key trends in the pneumonia therapeutics market are:
• Development of monoclonal antibodies is a notable emerging trend.
• Adoption of inhalable antibiotics is shaping the future of the market.
• There is growing attention towards mRNA-based vaccine innovation.
• Advancements in rapid point-of-care diagnostic platforms are making strong impacts.
Major players in the pneumonia therapeutics market are:
• Pfizer Inc.
• Roche AG
• Merck & Co. Inc.
• AbbVie Inc
• Bayer AG
• Sanofi S.A.
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Shionogi & Co. Ltd
• Lupin Limited
• Swedish Orphan Biovitrum AB
• Nabriva Therapeutics plc
• TaiGen Biotechnology Co. Ltd
• Aridis Pharmaceuticals Inc.
• Tergene Biotech Limited
North America was the largest region in the pneumonia therapeutics market in 2024